Structural optimization of icaritin for advanced cancer: novel carbamates via oral administration,New Journal of Chemistry

当前位置： X-MOL 学术 › New J. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Structural optimization of icaritin for advanced cancer: novel carbamates via oral administration
New Journal of Chemistry ( IF 3.3 ) Pub Date : 2024-04-09 , DOI: 10.1039/d3nj05723b
Fengxiao Li ₁ , Weiping Wang ₁ , Jiaqi Fan ₁ , Yixiu Zhai ₁ , Jiaming Zhang ₁ , Tianhong Zhang ₁ , Qikun Jiang _{1,

2}

Affiliation

Advanced cancer is a leading cause of disability and mortality globally, with an ever-increasing incidence. In China, icaritin (ICT), a naturally occurring compound with established efficacy and safety, is widely administered orally for treating advanced cancer. However, due to significant phase II metabolism with a positional preference on 3-OH, its usage in clinical settings is restricted. To minimize the phase II metabolism, we synthesized N-monomethyl carbamate and N-monoethyl carbamate (3N-Me and 3N-Et) that were modified on the 3-OH group of ICT. Just as we expected, 3N-Me and 3N-Et remained stable during the absorption process, and they were metabolized in plasma to the ICT. The rate of phase II metabolism of carbamate in vitro was significantly lower compared to ICT. Additionally, the different forms of the carbamate resulted in similar or stronger cytotoxicity than ICT. Furthermore, the pharmacokinetics of 3N-Me and 3N-Et were studied after oral administration. Compared to ICT, the oral administration of 3N-Me led to a significantly enhanced bioavailability of ICT and 3N-Me in rats. It was found that 3N-Me was more effective in exerting its anticancer pharmacological activity and was equally safe as the form of ICT alone. Additionally, our results indicated that ICT and 3N-Me both have beneficial effects on immunotoxicity and spleen functions altered by cancer. This suggests the potential for further development of 3N-Me medicine in the anticancer field for oral administration.

更新日期：2024-04-09

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>